< Back to previous page
Researcher
Johan Neyts
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 30 Sep 2002 - Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 90
- Understanding Congenital Zika virus Syndrome in a Mouse Model to Develop Disease Modifying Therapies.From1 Oct 2025 → TodayFunding: BOF - postdoctoral mandates
- Towards Strategies for the Treatment and Prevention of Mpox InfectionsFrom25 Sep 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- TPVC - Antiviral researchFrom13 Feb 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Developing effective antivirals for the treatment of West Nile neuroinvasive diseaseFrom16 Sep 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Core research facility for image-based, non-invasive, longitudinal evaluation of functional, structural and physiological adaptations in experimental small animal models through high-resolution micro-CTFrom1 May 2024 → TodayFunding: FWO Medium Size Research Infrastructure
- European Viral Outbreak Response AllianceFrom1 Jan 2024 → TodayFunding: HORIZON.1.3 - Research Infrastructures
- New AntiVirals for Infections with Pandemic PotentialFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- Developing broad-spectrum antiviral drugs for pandemic preparednessFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- MabMine: Breaking the barrier in conventional antibody discoveryFrom1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Classic and new strategies to fight alphavirusesFrom18 Aug 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 616
- Antiviral activities of phenylalanine derivatives carrying carboxylic acid bioisosteres against chikungunya and parainfluenza virus type 3.(2025)Published in: Bioorganic & Medicinal ChemistryISSN: 0968-0896Volume: 130Pages: 118343
- 2-amido-3-aryl-4-methyl-thiazole derivatives as broad-spectrum anti-rhinoviral agents.(2025)Published in: European Journal of Medicinal ChemistryISSN: 0223-5234Issue: Pt 3Volume: 302Pages: 118318
- Synthesis and antiviral activity of thiazolyl hydrazones against dengue virus.(2025)Published in: Bioorganic & Medicinal Chemistry LettersISSN: 0960-894XVolume: 130Pages: 130436
- Discovery of Novel Arylethynyltriazole Ribonucleosides with Selective and Effective Antiviral and Antiproliferative Activity (vol 52, pg 1144, 2009)(2025)Published in: Journal of Medicinal ChemistryISSN: 0022-2623Issue: 19Volume: 68Pages: 20851 - 20851
- Identification and Exploration of a Series of SARS-Cov-2 MPro Cyano-Based Inhibitors Revealing Ortho-Substitution Effects within the P3 Biphenyl Group(2025)Published in: ACS Medicinal Chemistry LettersISSN: 1948-5875Issue: 10Volume: 16
- 1′-Cyanocytidine-5′-isobutyryl is a potent SARS-CoV-2 inhibitor in culture and infected Syrian hamsters(2025)Published in: Science AdvancesISSN: 2375-2548Issue: 40Volume: 11
- Design, synthesis and evaluation of arylpurine-based sinefungin mimetics as zika virus methyltransferase inhibitors(2025)Published in: RSC AdvancesISSN: 2046-2069Issue: 44Volume: 15Pages: 37309 - 37324
- High-throughput split-GFP antiviral screening assay against fusogenic paramyxoviruses(2025)Published in: Antiviral ResISSN: 0166-3542Volume: 241
- The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness(2025)Published in: Clinical Infectious DiseasesISSN: 1058-4838
- Meeting report: 38th international conference on antiviral research in Las Vegas, United States of America, March 17-21, 2025(2025)Published in: Antiviral ResISSN: 0166-3542Volume: 241
Patents
1 - 10 of 10
- Viral replication inhibitors
- Antiviral 1,3-di-oxo-indene compounds
- Live-attenuated flaviruses with heterologous antigens
- 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
- Live-attenuated flaviruses with heterologous antigens
- Antiviral 1,3-di-oxo-indene compounds
- Coronavirus vaccines
- Neutralizing anti-sars-cov-2 human antibodies
- Neutralizing anti-sars-cov-2 human antibodies
- Corona virus binders